Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago.
- 08/07/2024
|
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
- Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
- 06/27/2024
|
Biodesix Named to Inc. Magazine's 2024 āBest Workplacesā
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of a comprehensive, data-driven measurement process to identify which American companies have excelled in creating exceptional workplaces with great company cultures. After collecting data from thousands of submissions, Inc. selected 543 honorees this year. Each company that was nomina.
- 06/18/2024
|
Biodesix to Participate in Two Investor Conferences in June
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44th Annual Growth Stock Conference Presentation and 1x1 Meetings Presentation Date and Time: Tuesday, June 4, 2024 at 10:40 AM CT Location: Chicago, IL Jefferies Global Healthcare Conference Presentation and 1x1 Meetings Presentation Date.
- 05/28/2024
|
Biodesix to Present New Data on the Nodify XL2Ā® Test at ATS 2024 Annual Meeting
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society (ATS) International Conference in San Diego, California. The presentation, titled "Performance comparison of a blood-based integrated classifier for lung nodule risk stratification in patients with versus without emphysema," will be presented by Arthur Romero MD, MSC, FCCP, As.
- 05/21/2024
|
Biodesix, Inc. (BDSX) Q1 2024 Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Scott Hutton - CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Thomas Flaten - Lake Street Capital Markets Operator Welcome to the Biodesix Q1 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
- 05/10/2024
|
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.24 per share a year ago.
- 05/08/2024
|
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024. 2024 RBCCM Global Healthcare Conference Fireside Chat Date: Tuesday, May 14, 2024 Fireside Chat Time: 1:35 PM ET Location: InterContinental New York.
- 05/07/2024
|
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast vi.
- 04/24/2024
|
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical s.
- 04/09/2024
|
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
- LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share. Subject to.
- 04/05/2024
|
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
- LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with t.
- 03/25/2024
|
Biodesix, Inc. (BDSX) Q4 2023 Earnings Call Transcript
- Biodesix, Inc. (BDSX) Q4 2023 Earnings Call Transcript
- 03/01/2024
|
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023). āI am exceptionally proud of the Biodesix team and our record of accomplishments in 2023,ā said Scott Hutton, CEO of Biodesix. āWe were focused on three goals: driving increased revenue through adoption of our Lung Diagnosti.
- 03/01/2024
|
Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
- LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024. TD Cowen 44th Annual Health Care Conference Presentation Date: Monday, March 4, 2024 Presentation Time: 10:30 AM ET Location: Marriot Copley Pla.
- 02/26/2024
|
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the w.
- 02/16/2024
|
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
- Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local government spending, and overall expectations suggest that, while there may be a short slowdown, the U.S. economy is anticipated to remain on a positive trajectory in 2024.
- 01/26/2024
|
3 Medical Services Stocks to Buy as Industry Trends Improve
- The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most.
- 11/24/2023
|
Biodesix Enhances Access to Nodify LungĀ® Testing with Launch of New Blood Draw Method
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+ā¢ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient's upper arm. Blood-based Nodify Lung testing, comprised of the Nodify CDTĀ® and N.
- 11/14/2023
|
Biodesix, Inc. (BDSX) Q3 2023 Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Kyle Mikson - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the Biodesix Quarter Three 2023 Earnings Conference Call.
- 11/11/2023
|
Biodesix to Participate in Two Upcoming Investor Conferences in November
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum Presentation and 1x1 Meetings Presentation Date and Time: Thursday, November 16, 2023 at 3:00 PM ET Location: Westin NY Grand Central, New York, NY Piper Sandler 35th Annual Health.
- 11/09/2023
|
Biodesix Announces Third Quarter 2023 Results and Highlights
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update. āI am pleased to announce yet another impressive quarter of growth at Biodesix,ā said Scott Hutton, President and Chief Executive Officer. āThe team delivered over 10,400 Lung Diagnostics tests, growing 60% over the 6,500 tests delive.
- 11/07/2023
|
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcas.
- 10/24/2023
|
Biodesix to Present New Data on Nodify LungĀ® Testing at CHEST 2023 Annual Meeting
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, HawaiŹ»i. These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules. The first abstract, titled "Real-World Impact of a Blood-Based Integrated Classifier.
- 10/03/2023
|
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
- Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OI Glass (OI), KE Hodlings (BEKE), Biodesix (BDSX) and Phunware (PHUN).
- 09/08/2023
|
Biodesix to Participate in Two Upcoming Investor Conferences in September
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat and 1x1 Meetings Fireside Date: Tuesday, September 12, 2023 Fireside Time: 12:15 PM ET Location: Sheraton Hotel, New York, NY H.C. Wainwright 25th Annual Global I.
- 09/05/2023
|
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago.
- 08/07/2023
|
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the w.
- 07/24/2023
|
Biodesix, Inc. (BDSX) Q1 2023 Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Operator Good day, and thank you for standing by and welcome to the Biodesix First Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.
- 05/14/2023
|
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.50 per share a year ago.
- 05/11/2023
|
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May 11. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webca.
- 04/27/2023
|
Biodesix, Inc. (BDSX) Q4 2022 Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Andrew Brackmann - William Blair Operator Good day, and thank you for standing by. Welcome to the Biodesix Fourth Quarter and Year-End 2022 Earnings Conference Call.
- 03/06/2023
|
Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates
- Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -7.69% and 10.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/06/2023
|
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day.
- 02/21/2023
|
Biodesix Appears Poised For 2023 Growth
- Biodesix, Inc. published its Q3 financial results on November 3, 2022. The firm provides an array of lung cancer diagnostic tests in the U.S.
- 02/13/2023
|
Biodesix, Inc. (BDSX) Q3 2022 Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Representatives Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Chris Brinzey - Investor Relations Conference Call Participants Andrew Brackmann - William Blair Max Masucci - Cowen & Company Kyle Mikson - Canaccord Genuine Operator Good day! And thank you for standing by.
- 11/06/2022
|
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
- BOULDER, Colo.
- 10/20/2022
|
Biodesix to Participate in Two Upcoming Investor Conferences in September
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live
- 09/06/2022
|
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2022 Results - Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Max Masucci - Cowen Kyle Mikson - Canaccord Operator Good morning. My name is Joanne and I will be your conference operator today.
- 08/06/2022
|
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 14.89% and 28.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022. Canaccord Genuity 42nd Annual Growth Conference Date: Wednesday, August 10, 2022 Time: 3:00 PM ET Location: InterContinental Boston The presentation will be webcast live and available for r
- 08/03/2022
|
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStratĀ® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and Oncology) Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC2022) on Aug
- 07/20/2022
|
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day. Dial-in and call details are a
- 07/19/2022
|
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
- BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL. 42nd Annual William Blair Growth Stock Conference Date: Wednesday, June 8, 2022 Time: 9:20 a.m. CT In addition to the presentation, the management t
- 06/01/2022
|
Biodesix: Bad Diagnosis
- Biodesix has been a terrible business and stock since its offering. Even a short-lived pandemic-related momentum run could not inspire confidence or profits.
- 05/26/2022
|
Biodesix to Present at the H.C. Wainwright Global Investment Conference
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022. H.C. Wainwright Global Investment Conference Date: Tuesday, May 24, 2022 Pre-recorded on-demand presentation available beginning at 7:00 AM ET The on-demand presentation will be availa
- 05/17/2022
|
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2022 Results - Earnings Call Transcript
- Biodesix, Inc. (NASDAQ:BDSX ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Chris Brinzey - IR Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Brian Weinstein - William Blair & Company Kyle Mikson - Canaccord Genuity Max Masucci - Cowen and Company Operator Hello. Thank you for standing by, and welcome to Biodesix First Quarter 2022 Earnings Conference Call.
- 05/11/2022
|
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
- Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2022
|
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on Wednesday, May 11. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day. Dial-in and call details are as
- 04/27/2022
|
Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing
- Biodesix, Inc. (BDSX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 03/15/2022
|
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q4 2021 Results - Earnings Call Transcript
- Biodesix, Inc. (BDSX) CEO Scott Hutton on Q4 2021 Results - Earnings Call Transcript
- 03/14/2022
|
Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates
- Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/14/2022
|
Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for
- Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/07/2022
|
Biodesix to Present at Cowen's 42nd Annual Healthcare Conference
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at Cowen's 42nd Annual Healthcare Conference being held virtually March 7-9, 2022. Cowen's 42nd Annual Healthcare Conference Date: Tuesday, March 8, 2022 Time: 2:50 PM ET The presentation will be webcast live and available for replay under āNews & Eventsā in the Investo
- 03/01/2022
|
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022. BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Date: Wednesday, February 16, 2022 Time: 4:30 PM ET
- 02/09/2022
|
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
- Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 0.00% and 8.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/15/2021
|
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q3 2021 Results - Earnings Call Transcript
- Biodesix, Inc. (BDSX) CEO Scott Hutton on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021. Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum Date: Thursday, November 18, 2021
- 11/11/2021
|
Biodesix, Inc. (BDSX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/08/2021
|
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 9:00 a.m. Eastern Time on the same day. Dial-in and call details
- 11/01/2021
|
Biodesix Announces New Data on Nodify LungĀ® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly emerging data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2Ā® Test - ORACLE [NCT03766958]), demonstrating that incorporation of this blood-based test in t
- 10/13/2021
|
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). The Role of Serum Proteomic Signature in Predicting Survival by PD-L1 Status in Patients with Non-Small Cell Lung Cancer R
- 09/16/2021
|
Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference being held virtually September 9-10 and September 13-15, 2021. Morgan Stanley Virtual 19th Annual Global Healthcare Conference Date: Thursday, September 9, 2021 Time: 4:15 PM ET The fires
- 09/02/2021
|
Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on results of two independent inspections conducted by CAP and BSI inspectors. The CAP advised
- 08/25/2021
|
4 Stocks Insiders Are Buying
- When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
- 08/24/2021
|
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2021 Results - Earnings Call Transcript
- Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday, August 10. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call details are a
- 07/27/2021
|
Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitled āA New Era in Precision Medicine - Uncovering the Depth & Breadth of the Plasma Proteome with Novel Proteomi
- 06/17/2021
|
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test (cPassā¢ Neutralization Test Kit, GenScript Inc.). The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) and is the first and o
- 06/15/2021
|
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
- BOULDER, Colo. & SAN FRANCISCO--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc.Ā (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share health data. Through this partnership, Biodesix will anonymize the lung cancer portion of their expansive sample and data biobank using Datavant's proprietary tokenization process and
- 06/04/2021
|
BDSX Stock Price: Over 8% Increase Pre-Market Explanation
- The stock price of Biodesix, Inc. (Nasdaq: BDSX) increased by over 8% pre-market. This is why it happened.
- 05/26/2021
|
First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker
- SAN CARLOS, Calif. and BOULDER, Colo.
- 05/26/2021
|
Biodesix to Present at the William Blair 41st Annual Growth Stock Conference
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021. William Blair 41st Annual Growth Stock Conference Date: Wednesday, June 2, 2021 Time: 2:00 PM CT The presentation will be webcast live and available for replay under āNews & Ev
- 05/25/2021
|
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2021 Results - Earnings Call Transcript
- Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2021 Results - Earnings Call Transcript
- 05/11/2021
|
Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with GenScript Biotech Corporation, a webinar to present novel data on the rapid detection of total SARS-CoV-2 neutralizing antibodies using cPassā¢ technology. Neutralizing antibodies may specifically block the interaction between the receptor binding protein on SARS-CoV-2, and the host cell's membrane receptor protein, t
- 04/26/2021
|
Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021
- BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call details are as f
- 04/26/2021
|
Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management
- BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Pulmonary disease expert, Dr. Susan Garwood, is hosted by CHEST to discuss standardized risk assessment to inform lung nodule management
- 04/22/2021
|
Biodesix Announces Fourth Quarter and Full Year 2020 Results
- BOULDER, Colo.--(BUSINESS WIRE)--Biodesix releases fourth quarter and full year 2020 results
- 03/16/2021
|
Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021
- BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call d
- 03/09/2021
|
Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021
- BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021. The Healthcare Technology Report noted that the past twelve months, more than any other period in recent history, have showcased the outstanding talent, ingenuity, and determination of the world's leading bio
- 02/25/2021
|
Biodesix to Participate in Two February Conferences
- BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precision Oncology Day, which is being held February 17, 2021. Event Details: Event: Ā Ā BTIG Virtual MedTech, Digital
- 02/12/2021
|
Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems
- BOULDER, Co.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of a new AI-based COVID-19 algorithm and the important data from a related study. The paper, entitled, āPredicting Prognosis in COVID-19 Patients using Machine Learning and Readily Available Clinical Data,ā demonstrates the AI-based algorithm's ability to rapidly and accurately help physicians pred
- 02/09/2021
|
Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine
- BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton was selected as the CEO of the Year, 2020 ā The USA by CEO Monthly. The magazine seeks to honor CEOs whose commitment to promoting business excellence, determination and innovative approaches help them take a business to the next level. Hutton was selected from a wide range of nominees for his r
- 02/02/2021
|
Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference
- BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings from these recent studies demonstrate that an individual patient's immune profile can provide information to suppor
- 01/26/2021
|
U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday Week
- The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 million at a $4.4 billion market cap.
- 11/22/2020
|
Biodesix: Challenged From The Start
- Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.
- 11/01/2020
|
